Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
| ▸ | AKT2 | P31751 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16975269 | 0.93 | PIK3C3 (0.37) | ABL1 | |
| SCHEMBL16975210 | 0.91 | AXL (0.36) | — | |
| SCHEMBL16975333 | 0.90 | NPY5R (0.41) | ABL1 | |
| SCHEMBL16975235 | 0.88 | ABL1 (0.34) | ABL1 | |
| SCHEMBL16975244 | 0.88 | ABL1 (0.34) | ABL1 | |
| SCHEMBL16975354 | 0.88 | ABL1 (0.34) | ABL1 | |
| SCHEMBL16975312 | 0.87 | ABL1 (0.37) | ABL1 | |
| SCHEMBL16975277 | 0.86 | NPC1 (0.41) | ABL1PIK3CA | |
| SCHEMBL16975230 | 0.86 | NPC1 (0.41) | ABL1PIK3CA | |
| SCHEMBL16975263 | 0.86 | LMNA (0.34) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | claimed |
| US-20170007615-A1 | Antibacterial Compounds | SPERO GYRASE, INC. | 2017-01-12 | — | — | US | disclosed |
| EP-3102203-A2 | ANTIBACTERIAL COMBINATIONS COMPRISING POLYMYXIN | SPERO GYRASE, INC. (US) | 2016-12-14 | — | — | EP | disclosed |
| WO-2015114452-A2 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD (GB) | 2015-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170007615-A1 | Antibacterial Compounds | CLPP, MRPL21, RELA | MAPT 4048/4885ABL1 294/4885AKT1 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.